EA201892707A1 - Способы и композиции для лечения целиакии, непереносимости глютена без целиакии и рефрактерной целиакии - Google Patents
Способы и композиции для лечения целиакии, непереносимости глютена без целиакии и рефрактерной целиакииInfo
- Publication number
- EA201892707A1 EA201892707A1 EA201892707A EA201892707A EA201892707A1 EA 201892707 A1 EA201892707 A1 EA 201892707A1 EA 201892707 A EA201892707 A EA 201892707A EA 201892707 A EA201892707 A EA 201892707A EA 201892707 A1 EA201892707 A1 EA 201892707A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- celiacia
- treatment
- refractory
- gluten
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2016/037708 WO2017217985A1 (fr) | 2016-06-15 | 2016-06-15 | Procédés et compositions pour le traitement de la maladie cœliaque, sensibilité au gluten non cœliaque et maladie cœliaque réfractaire |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201892707A1 true EA201892707A1 (ru) | 2019-05-31 |
Family
ID=56292925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201892707A EA201892707A1 (ru) | 2016-06-15 | 2016-06-15 | Способы и композиции для лечения целиакии, непереносимости глютена без целиакии и рефрактерной целиакии |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3472202A1 (fr) |
JP (2) | JP2019521981A (fr) |
CN (1) | CN109311972A (fr) |
AR (1) | AR108790A1 (fr) |
AU (2) | AU2016411388A1 (fr) |
BR (1) | BR112018076287A2 (fr) |
CA (1) | CA3020894A1 (fr) |
EA (1) | EA201892707A1 (fr) |
MX (2) | MX2024001374A (fr) |
TW (2) | TW201803591A (fr) |
WO (1) | WO2017217985A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3558369A4 (fr) | 2016-12-21 | 2020-09-09 | Cephalon, Inc. | Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations |
CN113329771A (zh) * | 2018-10-31 | 2021-08-31 | 迪赞纳生命科学公开有限公司 | 治疗炎症性和自身免疫性疾病的组合物和方法 |
MX2024001934A (es) | 2021-08-12 | 2024-03-04 | Amgen Inc | Formulaciones de anticuerpos. |
WO2024028448A1 (fr) | 2022-08-04 | 2024-02-08 | Calypso Biotech Sa | Inhibiteurs d'il-15 utiles pour le traitement de la dermatite atopique |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247304B2 (en) * | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
RS20050724A (en) * | 2003-02-26 | 2007-11-15 | Genmab A/S., | Human antibodies specific for interleukin 15(il-15) |
SG172855A1 (en) * | 2009-01-29 | 2011-08-29 | Abbott Lab | Il-1 binding proteins |
WO2011031986A1 (fr) * | 2009-09-10 | 2011-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health | Dosages du récepteur soluble à il-15 alpha |
EP2963057A1 (fr) * | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Anticorps pour IL-15 |
-
2016
- 2016-06-15 MX MX2024001374A patent/MX2024001374A/es unknown
- 2016-06-15 MX MX2018015363A patent/MX2018015363A/es unknown
- 2016-06-15 JP JP2018565345A patent/JP2019521981A/ja active Pending
- 2016-06-15 CN CN201680086774.8A patent/CN109311972A/zh active Pending
- 2016-06-15 AU AU2016411388A patent/AU2016411388A1/en not_active Abandoned
- 2016-06-15 WO PCT/US2016/037708 patent/WO2017217985A1/fr unknown
- 2016-06-15 EP EP16733804.5A patent/EP3472202A1/fr active Pending
- 2016-06-15 CA CA3020894A patent/CA3020894A1/fr active Pending
- 2016-06-15 EA EA201892707A patent/EA201892707A1/ru unknown
- 2016-06-15 BR BR112018076287-3A patent/BR112018076287A2/pt active Search and Examination
-
2017
- 2017-06-15 AR ARP170101652A patent/AR108790A1/es unknown
- 2017-06-15 TW TW106119998A patent/TW201803591A/zh unknown
- 2017-06-15 TW TW111144466A patent/TW202327653A/zh unknown
-
2021
- 2021-09-24 JP JP2021155175A patent/JP2022001577A/ja active Pending
-
2024
- 2024-07-31 AU AU2024205264A patent/AU2024205264A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2024205264A1 (en) | 2024-08-22 |
CN109311972A (zh) | 2019-02-05 |
WO2017217985A1 (fr) | 2017-12-21 |
MX2024001374A (es) | 2024-02-27 |
TW201803591A (zh) | 2018-02-01 |
AU2016411388A1 (en) | 2018-11-08 |
TW202327653A (zh) | 2023-07-16 |
JP2019521981A (ja) | 2019-08-08 |
MX2018015363A (es) | 2019-04-15 |
CA3020894A1 (fr) | 2017-12-21 |
JP2022001577A (ja) | 2022-01-06 |
BR112018076287A2 (pt) | 2019-03-26 |
EP3472202A1 (fr) | 2019-04-24 |
AR108790A1 (es) | 2018-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122184T1 (el) | Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη | |
CY1121473T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
CY1122344T1 (el) | Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων | |
CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
EA201891202A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890049A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890047A1 (ru) | Композиции, содержащие бактериальные штаммы | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
EA201890051A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201691872A1 (ru) | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств | |
EA201890493A1 (ru) | РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ | |
EA201790413A1 (ru) | Антитела против tigit | |
EA201691114A1 (ru) | Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии | |
EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
EA201692109A1 (ru) | Варианты антител к фактору d и их применение | |
SA518391831B1 (ar) | تركيبات وطرق لخفض تعبير البروتين تاو | |
EA201692091A1 (ru) | Хиноксалиновые соединения и их применение | |
EA201890097A1 (ru) | Индукция регуляторных т-клеток lamina propria | |
EA201892707A1 (ru) | Способы и композиции для лечения целиакии, непереносимости глютена без целиакии и рефрактерной целиакии | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
EA201791937A1 (ru) | Противовоспалительные полипептиды | |
EA201790893A1 (ru) | Способы лечения офтальмологических расстройств | |
JOP20190164B1 (ar) | تركيبات وطرق لعلاج داء فاربر |